Logo image of PFE.DE

PFIZER INC (PFE.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:PFE - US7170811035 - Common Stock

21.86 EUR
-0.04 (-0.16%)
Last: 1/8/2026, 7:00:00 PM

PFE.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap124.29B
Revenue(TTM)62.79B
Net Income(TTM)9.83B
Shares5.69B
Float5.68B
52 Week High26.25
52 Week Low18.57
Yearly Dividend1.43
Dividend Yield6.91%
EPS(TTM)2.74
PE7.98
Fwd PE8.41
Earnings (Next)02-02 2026-02-02/amc
IPO1944-01-17
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PFE.DE short term performance overview.The bars show the price performance of PFE.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 1 2

PFE.DE long term performance overview.The bars show the price performance of PFE.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of PFE.DE is 21.86 EUR. In the past month the price decreased by -0.84%. In the past year, price decreased by -17.07%.

PFIZER INC / PFE Daily stock chart

PFE.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
SAN.PA SANOFI 10.91 201.34B
SNW.DE SANOFI 10.91 201.39B
1SAN.MI SANOFI 10.89 201.12B
MRK.DE MERCK KGAA 14.97 55.52B
UCB.BR UCB SA 39.33 49.11B
UNC.DE UCB SA 39.33 49.11B
BAYN.DE BAYER AG-REG 7.4 38.84B
1BAYN.MI BAYER AG-REG 7.36 38.61B
IPN.PA IPSEN 12.34 10.62B
REC.MI RECORDATI INDUSTRIA CHIMICA 25.03 10.31B
TUB.BR FINANCIERE DE TUBIZE 107.45 9.95B
1JAZZ.MI JAZZ PHARMACEUTICALS PLC 21.08 8.94B

About PFE.DE

Company Profile

PFE logo image Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK US

Employees: 81000

PFE Company Website

PFE Investor Relations

Phone: 12127332323

PFIZER INC / PFE.DE FAQ

What does PFIZER INC do?

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.


Can you provide the latest stock price for PFIZER INC?

The current stock price of PFE.DE is 21.86 EUR. The price decreased by -0.16% in the last trading session.


Does PFE stock pay dividends?

PFIZER INC (PFE.DE) has a dividend yield of 6.91%. The yearly dividend amount is currently 1.43.


What is the ChartMill technical and fundamental rating of PFE stock?

PFE.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the GICS sector and industry of PFE stock?

PFIZER INC (PFE.DE) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the PE ratio for PFE stock?

The PE ratio for PFIZER INC (PFE.DE) is 7.98. This is based on the reported non-GAAP earnings per share of 2.74 and the current share price of 21.86 EUR.


Can you provide the upcoming earnings date for PFIZER INC?

PFIZER INC (PFE.DE) will report earnings on 2026-02-02, after the market close.


PFE.DE Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE is a bad performer in the overall market: 84.85% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PFE.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. There are concerns on the financial health of PFE.DE while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PFE.DE Financial Highlights

Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.74. The EPS increased by 24.03% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.65%
ROA 4.71%
ROE 10.59%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%-17.92%
Sales Q2Q%-5.92%
EPS 1Y (TTM)24.03%
Revenue 1Y (TTM)3.9%

PFE.DE Forecast & Estimates

33 analysts have analysed PFE.DE and the average price target is 25.24 EUR. This implies a price increase of 15.47% is expected in the next year compared to the current price of 21.86.

For the next year, analysts expect an EPS growth of 1.34% and a revenue growth -1.36% for PFE.DE


Analysts
Analysts71.52
Price Target25.24 (15.46%)
EPS Next Y1.34%
Revenue Next Year-1.36%

PFE.DE Ownership

Ownership
Inst Owners67.61%
Ins Owners0.02%
Short Float %N/A
Short RatioN/A